CNS Pharmaceuticals, Inc. Earnings Per Share Diluted

Quick Answer

CNS Pharmaceuticals, Inc. reported Earnings Per Share Diluted of $35.75 (loss) per share for the year ending 2025.

  • CNS Pharmaceuticals, Inc. showed an increase of +92.3% in Earnings Per Share Diluted from 2024 to 2025.
  • This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), CNS Pharmaceuticals, Inc.'s Earnings Per Share Diluted has declined by 116.7%.
  • Historical annual values: Fiscal year 2025: $35.75 (loss) per share | Fiscal year 2024: $466.89 (loss) per share | Fiscal year 2023: $12,509.11 (loss) per share | Fiscal year 2022: $11.22 (loss) per share | Fiscal year 2021: $16.50 (loss) per share.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: